Physician Network Connections Associated With Faster De-Adoption of Dronedarone for Permanent Atrial Fibrillation.
Chad StecherAlexander EverhartLaura Barrie SmithAnupam B JenaJoseph R RossNihar R DesaiNilay ShahPinar Karaca-MandicPublished in: Circulation. Cardiovascular quality and outcomes (2021)
After controlling for a wide range of patient, physician, and geographic characteristics, physicians with a greater number of network connections were faster de-adopters of dronedarone for patients with permanent atrial fibrillation after the PALLAS trial and subsequent United States Food and Drug Administration black box warning detailed the harmfulness of dronedarone for these patients. Policies for improving physicians' responsiveness to new medical information should consider utilizing the influence of these important professional network relationships.
Keyphrases
- primary care
- atrial fibrillation
- end stage renal disease
- emergency department
- drug administration
- heart failure
- chronic kidney disease
- ejection fraction
- newly diagnosed
- oral anticoagulants
- catheter ablation
- public health
- peritoneal dialysis
- clinical trial
- left atrial appendage
- direct oral anticoagulants
- randomized controlled trial
- percutaneous coronary intervention
- study protocol
- transcription factor
- case report
- health information
- coronary artery disease
- patient reported outcomes
- acute coronary syndrome
- network analysis
- climate change
- human health